---
theme: academic
layout: cover
class: text-white
coverAuthor: beau hilton 
coverAuthorUrl: https://www.beauhilton.com
coverDate: 2022-09-09T07:30
coverBackgroundUrl: ./images/b-cell.png
coverBackgroundSource: WikiJournal of Medicine 1
coverBackgroundSourceUrl: https://commons.wikimedia.org/wiki/File:Blausen_0624_Lymphocyte_B_cell_(crop).png
themeConfig:
  paginationX: r
  paginationY: t
  paginationPagesDisabled: [1]
title: Management of B-ALL in older adults
info: |
  # Management of B-ALL in older adults
  Case Conference 2022-09-09, [Beau Hilton](https://www.beauhilton.com)

---

# Management of B-ALL in older adults

<!-- download: true -->
<!-- exportFilename: 2022-09-09-b-all-older-adults -->

CME 49408

<Pagination classNames="text-gray-300" />

---
layout: default
---

# Case presentation

75M w hx indolent chronic ITP, 
prostate Ca (s/p XRT+ADT early 2010s), 
CAD, AVR 2015, HFrEF (LVEF 30% 2022), 
presented with several months of dyspnea on exertion, sore throat, and extreme fatigue. 

Plts had been high 80s-low 100s since mid 2015 (s/p steroids, rituximab).

2014 BMBx variably cellular <10% to 30-40% 
with mild erythroid atypia and karyotype 4 of 20 cells with -Y.

Notable labs on presentation:

- WBC 1.46, ANC 580
- Hgb 9.1 (wnl a few months earlier)
- plt 35 -> 16 on recheck two weeks later (97 a few months earlier)
- T bili 3.89 (D bili 2.38), ALK 368, ALT 183, AST 75

ferritin 516.89, folate >20, Fe 205, TIBC 323.85, transferrin 255,
TSH 8.1506, fT4 0.93, Cr 1.42; HbA1c 6.5; PSA <0.100


---
layout: default
---

# Case presentation continued

Exam notable for jaundice (1wk per wife), no edema, JVP wnl

BMBx

- \>90% blasts
- positive [CD34, HLA-DR, CD38, TdT, moderate CD58,  moderate cytoplasmic CD22, and moderate cytoplasmic CD79a]
- heterogeneous [CD19, CD38, dim CD10, CD20, cytoplasmic CD19]
- negative [CD33, CD11b, CD15, CD16, CD14, CD64, CD2, CD56, cytoCD3, CD117, and myeloperoxidase.]
- negative for BCR-ABL including breakapart
- Ph-like pending
- complex karyotype (specifics not available)

---
layout: default
---

# Defining the cohort

<div class="grid grid-cols-2 grid-rows-2 gap-4">

<div>

### Age

Just a number, as they say.

</div>

<div>

### Karnofsky Performance Status

Defined in [1948](https://doi.org/10.1002/1097-0142(194811)1:4%3C634::AID-CNCR2820010410%3E3.0.CO;2-L), 
in an early paper on nitrogen mustards. 
100% is completely healthy, 
0% is dead.
10% is <a2 href="mostly-dead.gif">mostly dead</a2>.

<style>
a2:hover:after {
    content: url(mostly-dead.gif); 
    display: block;
    position: absolute;
    left: 123px; 
    top: 56px; 
}
</style>


[MDCalc](https://www.mdcalc.com/calc/3168/karnofsky-performance-status-scale)

</div>

<div>

### ECOG Performance Status

Defined in [1982](http://journals.lww.com/00000421-198212000-00014) 
by the Eastern Cooperative Oncology Group, 
a simplified version of Karnofsky. 0 is completely healthy, 5 is dead, 2.5 is the VA special.

[MDCalc](https://www.mdcalc.com/calc/3170/eastern-cooperative-oncology-group-ecog-performance-status)

</div>

<div>


### Charlson Comorbidity Index CCI

Defined in [1987](https://doi.org/10.1016/0021-9681(87)90171-8), somewhat out of date (e.g. "AIDS" gets 6 points by itself), but among the more useful standardized measures of biological (rather than chronological) age.

[MDCalc](https://www.mdcalc.com/calc/3917/charlson-comorbidity-index-cci)

</div>

</div>

---
layout: figure-side
figureCaption: ECOG PS scoresj
figureFootnoteNumber: 1
figureUrl: ./images/prephase-ecog-dlbcl.png
---

# Pre-Phase Chemotherapy

- prednisone (GRAALL-2003, 7d prior to induction)
- Vincristine + prednisone (SWOG-7416 1983, CR ~20% in all comers)

<Footnotes separator>
  <Footnote :number=1><a href="https://doi.org/10.1186/s43046-022-00116-5" rel="noreferrer" target="_blank">Rudresha 2022</a></Footnote>
</Footnotes>

---
layout: figure
figureCaption: inotuzumab ozogamicin in older adults
figureFootnoteNumber: 1
figureUrl: ./images/b-all-age-ecog-curves.png
---

# Survival in Older Adults


<Footnotes separator>
  <Footnote :number=1><a href="https://doi.org/10.1186/s43046-022-00116-5" rel="noreferrer" target="_blank"></a></Footnote>
</Footnotes>

---
layout: figure
figureCaption: inotuzumab ozogamicin in older adults
figureFootnoteNumber: 1
figureUrl: ./images/io-km.png
---

# Inotuzumab

<Footnotes separator>
  <Footnote :number=1><a href="https://doi.org/10.1186/s43046-022-00116-5" rel="noreferrer" target="_blank"></a></Footnote>
</Footnotes>

---
layout: figure
figureCaption: novel therapies
figureFootnoteNumber: 1
figureUrl: ./images/novel-tx.png
---

<Footnotes separator>
  <Footnote :number=1><a href="https://doi.org/10.1186/s43046-022-00116-5" rel="noreferrer" target="_blank"></a></Footnote>
</Footnotes>
---
layout: index
indexEntries:
  - { title: "Sas V, Moisoiu V, Teodorescu P, et al. Approach to the Adult Acute Lymphoblastic Leukemia Patient. J Clin Med. 2019;8(8):1175. Published 2019 Aug 6. doi:10.3390/jcm8081175", uri: "https://doi.org/10.3390/jcm8081175" }
  - { title: "Short, Nicholas J et al. “Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.” Leukemia vol. 35,11 (2021): 3044-3058. doi:10.1038/s41375-021-01277-3", uri: "https://doi.org/10.1038/s41375-021-01277-3" }
  - { title: "Wenge DV, Wethmar K, Klar CA, et al. Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia. Cancers (Basel). 2022;14(3):565. Published 2022 Jan 23. doi:10.3390/cancers14030565
", uri: "https://doi.org/10.3390/cancers14030565" }
  - { title: "McCredie, K.B., Gehan, E.A., Freireich, E.J., Hewlett, J.S., Coltman, C.A., Jr., Hussein, K.K., Balcerzak, S.P. and Timothy Chen, T. (1983), Management of adult acute leukemia a southwest oncology group study. Cancer, 52: 958-966. https://doi.org/10.1002/1097-0142(19830915)52:6<958::AID-CNCR2820520604>3.0.CO;2-Z", uri: "https://doi.org/10.1002/1097-0142(19830915)52:6%3C958::aid-cncr2820520604%3E3.0.co;2-z"}
  - { title: "HemOnc.org B-cell lymphoblastic leukemia guidelines", uri: "https://hemonc.org/wiki/B-cell_acute_lymphoblastic_leukemia#Vincristine_.26_Prednisone"}
  - { title: "NCCN Guidelines", uri: (https://www.nccn.org/professionals/physician_gls/pdf/all.pdf)}
indexRedirectType: external
---

# index


